Squarepoint’s Lipocine LPCN Stock Holding History

Squarepoint’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,941	Closed	-$127K	–	3496
2021 Q1	$127K	Buy	4,941 +4,138	+515%	+$119K	﹤0.01%	2845
2020 Q4	$19K	Buy	+803	New	+$19.3K	﹤0.01%	2838

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Squarepoint's LPCN Position: Q2 2021 in Review

Squarepoint sold out of Lipocine (LPCN) in Q2 2021, closing a stake of 4,941 shares — an estimated $127K sold.

Squarepoint first reported a position in LPCN in Q4 2020 and held it in 2 quarters. The position peaked at $127K in Q1 2021. 32 funds tracked by Wall St. Rank hold LPCN as of Q2 2021.

Squarepoint reported no remaining Lipocine position as of Q2 2021 after selling out during the quarter.
Squarepoint sold 4,941 Lipocine shares in Q2 2021, an estimated $127K.
Squarepoint first reported a position in Lipocine in Q4 2020 and held it in 2 quarters.
Squarepoint's Lipocine position peaked at $127K in Q1 2021.
32 funds tracked by Wall St. Rank held Lipocine as of Q2 2021.

Based on Squarepoint's 13F filing for Q2 2021, filed 16 Aug 2021.